Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04778579
Other study ID # CART19-BE-02
Secondary ID
Status Active, not recruiting
Phase Phase 2
First received
Last updated
Start date May 11, 2021
Est. completion date December 31, 2025

Study information

Verified date August 2023
Source Institut d'Investigacions Biomèdiques August Pi i Sunyer
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To assess the efficacy (in terms of response rate and duration) of the infusion of ARI-0001 cells (Adult differentiated autologous T-cells from peripheral blood, expanded and transducted with a lentivirus to express a chimeric antigen receptor with anti-CD19 specificity [A3B1] conjugated to the 4-aBB and CD3z co-stimulatory regions) in patients with resistant or refractory CD19+ acute lymphoid leukemia


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 50
Est. completion date December 31, 2025
Est. primary completion date December 31, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: 1. Diagnoses of CD19+ acute lymphoid leukemia, with a life expectancy of less than 2 years that meet the following conditions: 1. Relapsed/refractory not candidate for transplantation (due to associated diseases or absence of donor) 2. in allogenic post-transplant relapse. 2. Measurable disease understood as the presence of measurable residual disease by flow cytometry in bone marrow or peripheral blood 3. Age less than 70 years (from 18 to 70). 4. ECOG functional status from 0 to 2 5. Life expectancy of at least 3 months. 6. Adequate venous access to perform a lymphapheresis. Absence of contraindications for it. 7. Signature of informed consent. Exclusion Criteria: 1. Treatment with any experimental or non-marketed substance within four weeks prior to recruitment, or actively participating in another therapeutic trial. 2. Previous treatment with CART therapy (commercial or experimental) 3. Diagnosis of another neoplasm, past or present. Patients may be included in complete remission for more than 3 years, or have a history of non-melanoma skin cancer or in-situ carcinoma resected completely. 4. Relief of central nervous system (CNS-3) at the time of inclusion. Inclusion will be permitted in patients with a lower grade (CNS-2) or CNS-3 who have responded to intrathecal chemotherapy. 5. Isolated extramedullary involvement (i.e. in the absence of minimal residual disease in peripheral blood, bone marrow, or cerebrospinal fluid) 6. Early relapse after transplantation (less than 3 months for mononuclear cell apheresis, less than 6 months for infusion of ARI-0001) 7. Active immunosuppressive treatment for graft-versus-host disease and other diseases. The use of corticosteroids to control leukaemia at the time of inclusion should be limited as much as possible and should be discontinued prior to infusion of ARI-0001 cells. 8. Active infection requiring systemic medical treatment such as chronic kidney infection, chronic lung infection or tuberculosis. 9. HIV infection. 10. Positive serology for hepatitis B, defined as a positive test for HBsAg. In addition, if the patient is HBsAg negative but has anti-HBc antibodies it will be necessary to perform a DNA test of the hepatitis B virus, and if the result is positive the patient will be excluded 11. Positive serology for hepatitis C, defined as a positive test for anti-VHC antibodies confirmed by RIBA 12. Concurrent uncontrolled medical illnesses including cardiac, renal, hepatic, gastrointestinal, endocrine, pulmonary, neurological or psychiatric diseases that in the opinion of the investigator are potential risk factors to the patient. 13. Severe organ involvement, defined as cardiac ejection fraction <40%; DLCO <40%; calculated glomerular filtrate <30 ml/min; or bilirubin > 3 times the upper limit of normality (unless Gilbert syndrome). 14. Pregnant or lactating women. Woman of childbearing potential should have a negative pregnancy test in the screening phase. 15. Women of childbearing potential, including those whose last menstrual cycle was in the year prior to screening, who are unable or unwilling to use highly effective contraceptive methods* from the start of the study to the completion of the study. 16. Men who cannot or do not wish to use highly effective contraceptive methods* from the beginning of the study until the end of the study -

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
ARI-0001 cells
Adult differentiated autologous T-cells from peripheral blood, expanded and transduced with a lentivirus to express a chimeric antigen receptor with anti-CD19 specificity (A3B1) conjugated with the co-stimulatory regions 4-1BB and CD3z

Locations

Country Name City State
Spain Hospital Universitari Germans Trias i Pujol Badalona Barcelona
Spain Hospital Clinic of Barcelona Barcelona
Spain Hospital de la Santa Creu i Sant Pau Barcelona
Spain Hospital 12 de Octubre Madrid
Spain Hospital General Universitario Gregorio Marañón Madrid
Spain Hospital Clínico Universitario Virgen de La Arrixaca Murcia
Spain Clínica Universidad de Navarra Pamplona Navarra
Spain Hospital Universitario de Salamanca Salamanca
Spain Hospital U. Virgen del Rocío Sevilla

Sponsors (3)

Lead Sponsor Collaborator
Sara V. Latorre Institut d'Investigacions Biomèdiques August Pi i Sunyer, Instituto de Salud Carlos III

Country where clinical trial is conducted

Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Response rate • Response rate with measurable residual disease negative by multiparametric flow cytometry 20 days after infusion
See also
  Status Clinical Trial Phase
Recruiting NCT05959720 - Adult Acute Lymphoblastic Leukemia Treated With Pediatric Regimen in Brazil
Recruiting NCT02933333 - G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor Phase 4
Completed NCT02953730 - The Study on the Pharmacokinetics of PEG-rhG-CSF in Children and Adolescents Phase 4
Completed NCT02767388 - Electrophysiological Biomarkers of Chemotherapy-related Cognitive Impairment and Recovery
Recruiting NCT03610438 - Feasibility and Effectiveness of Inotuzumab Ozogamicin in B-Cell Acute Lymphoblastic Leukemia Phase 2
Recruiting NCT05792007 - Study of the Medullary Microenvironment in Acute Childhood Leukemia N/A
Completed NCT02294552 - Post-transplantation Cyclophosphamide as GVHD Prophylaxis After HSCT Phase 2
Completed NCT01461538 - Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies Phase 2
Recruiting NCT04167683 - Muscle Dysfunction in Patients With Hematological Diseases Referred to Stem Cell Transplant
Recruiting NCT05150561 - Muscle Dysfunction in Patients With Haematological Diseases
Active, not recruiting NCT04669210 - PTCy and Ruxolitinib vs PTCy, Tacrolimus and MMF in MUD and Haploidentical HSCT Phase 2
Active, not recruiting NCT04013685 - Precision-T: A Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies Phase 1
Recruiting NCT02345915 - Evaluation of Adverse Long-term Effects in Young Adult Survivors of Acute Leukemia N/A
Completed NCT01720264 - Multicenter Phase II of CD26 Using Sitagliptin for Engraftment After UBC Transplant Phase 2
Not yet recruiting NCT02413021 - The Effect of Deferasirox on Response Rate of Acute Leukemia Patients Not Treated by Standard Chemotherapy Regimens Phase 1
Not yet recruiting NCT06427330 - Phase II Study of Post-Transplant Low-Dose Inotuzumab Ozogamicin to Prevent Relapse of Acute Lymphoblastic Leukemia Phase 2
Recruiting NCT03448393 - CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies Phase 1
Completed NCT03833180 - A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001) Phase 1
Active, not recruiting NCT03367299 - Sequential Chemotherapy and Blinatumomab to Improve MRD Response and Survival in Acute Lymphoblastic Leukemia Phase 2
Terminated NCT02435550 - iCare for Cancer Patients N/A